141 related articles for article (PubMed ID: 8597088)
1. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
2. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.
Srinivasan SK; Iversen P
J Clin Lab Anal; 1995; 9(2):129-37. PubMed ID: 7714665
[No Abstract] [Full Text] [Related]
3. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Levin AA
Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
7. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists.
Iversen PL; Cornish KG; Iversen LJ; Mata JE; Bylund DB
Toxicol Appl Pharmacol; 1999 Nov; 160(3):289-96. PubMed ID: 10544063
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oligonucleotides.
Agrawal S; Zhang R
Ciba Found Symp; 1997; 209():60-75; discussion 75-8. PubMed ID: 9383569
[TBL] [Abstract][Full Text] [Related]
9. An overview of progress in antisense therapeutics.
Crooke ST
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
[No Abstract] [Full Text] [Related]
10. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
11. Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells.
Etore F; Tenu JP; Teiger E; Adnot S; Lonchampt MO; Pirotzki E; Le Doan T
Biochem Pharmacol; 1998 May; 55(9):1465-73. PubMed ID: 10076539
[TBL] [Abstract][Full Text] [Related]
12. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
13. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of therapeutic oligonucleotides.
Diasio RB; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
[No Abstract] [Full Text] [Related]
16. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
[TBL] [Abstract][Full Text] [Related]
17. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
[TBL] [Abstract][Full Text] [Related]
19. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
[TBL] [Abstract][Full Text] [Related]
20. Use of a simple fractionation method to evaluate binding, internalization and intracellular distribution of oligonucleotides in vascular smooth muscle cells.
Eboue D; Auger R; Angiari C; Le Doan T; Tenu JP
Arch Physiol Biochem; 2003 Jul; 111(3):265-72. PubMed ID: 14972750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]